Search Results
Mar 18, 2026, 12:37 ET Linc Housing Starts Construction on 64 Senior Affordable Apartments in Long Beach
history, housing and community investment in one landmark location, advancing Linc's mission to build inclusive communities where people can thrive."Gene Rascon of the Historic St. Anthony Neighborhood Association added, "Our community has been looking forward to the activation and revitalization of a
More news about: Linc Housing
Mar 18, 2026, 12:19 ET QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Mar 18, 2026, 11:30 ET MGI Tech et Predica Diagnostics accélèrent le dépistage du cancer du col de l'utérus sur les plateformes DNBSEQ
du col de l'utérus. La solution intégrée offre :génotypage HPV simultané à haute résolution et profilage de l'expression du gène de l'hôteamélioration de la spécificité pour l'évaluation du risque de cancer du col de l'utérus et le triage HPV+analyse et rapports
More news about: MGI Tech Co., Ltd.
Mar 18, 2026, 10:20 ET Celiac Disease Foundation Launches Venture Fund to Transform the Future of Celiac Disease
platforms, provider training, certification systems, and scalable community toolsCures – Enzyme therapies, immune tolerance approaches, and gene and cell-based treatmentsThe Impact Fund is designed to serve as a repeatable engine for change by identifying promising innovations, providing
More news about: Celiac Disease Foundation
Mar 18, 2026, 10:00 ET New England Biolabs® releases EnClose™ Cell-free dbDNA™ Synthesis Kit in collaboration with Touchlight to accelerate DNA and RNA therapeutic development
viral vector manufacturing — such as adeno-associated virus (AAV) and lentiviral (LV) vectors, non-viral gene therapy and a variety of nucleic acid therapeutics, including mRNA therapeutics and gene editing. Furthermore, the enzymatic process excels at synthesizing difficult sequences, such as long poly(A)
More news about: New England Biolabs, Inc.
Mar 18, 2026, 10:00 ET A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
https://straitsresearch.com/report/cell-therapy-market2. Precedence Research, Cell and Gene Therapy Market Forecast — https://www.precedenceresearch.com/cell-and-gene-therapy-market 3. Grand View Research, CAR T-Cell Therapy
More news about: Equity Insider
Mar 18, 2026, 10:00 ET Cenevo's Labguru Drives Digital Lab Transformation for Pace® Life Sciences
clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced,
More news about: Cenevo
Mar 18, 2026, 09:55 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP
Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing
More news about: Levi & Korsinsky, LLP
Mar 18, 2026, 09:00 ET Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases
funding from the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research (Grant Number CLIN2-15547).
More news about: Aspen Neuroscience, Inc.
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Type: Poster Session: Experimental and Molecular Therapeutics: RNA, Gene and Cell Therapies, and Enabling Assay Technologies Date/Time: April 19, 2026,
More news about: Jazz Pharmaceuticals plc
Mar 18, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
24Abstract Presentation Number: 391In this study, researchers established models primarily resistant to TUSC2 gene therapy (REQORSA or Quar Oze) to find biomarkers indicative of TUSC2 gene therapy resistance in NSCLC cell lines, PDX-derived organoids (PDXOs), and patient-derived xenografts (PDXs). A
More news about: Genprex, Inc.
Mar 18, 2026, 05:00 ET Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
announced the launch of the Trillion Gene Atlas, a landmark scientific initiative to generate and model biological data at the trillion-gene scale. Launched in collaboration with Anthropic, Ultima Genomics and PacBio, and powered by NVIDIA AI infrastructure, the Trillion Gene Atlas aims to expand known evolutionary
More news about: Basecamp Research
Mar 18, 2026, 05:00 ET Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
announced the launch of the Trillion Gene Atlas, a landmark scientific initiative to generate and model biological data at the trillion-gene scale. Launched in collaboration with Anthropic, Ultima Genomics and PacBio, and powered by NVIDIA AI infrastructure, the Trillion Gene Atlas aims to expand known evolutionary
More news about: Basecamp Research
Mar 17, 2026, 22:34 ET Ribo präsentiert auf der RNA Leaders Europe Conference Daten zur extrahepatischen Wirkstoffabgabe
Nach dem Erfolg von RiboGalSTAR™ zur gezielten Ansprache leberspezifischer Gene mit sieben Programmen in der klinischen Entwicklung sowie zwei bedeutenden globalen Kooperations- und Lizenzvereinbarungen im Wert von mehr als 6,0
More news about: Suzhou Ribo Life Science Co., Ltd.
Mar 17, 2026, 19:00 ET Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data - Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 - at AACR Annual Meeting 2026
trialsVerismo's multi-chain KIR-CAR technology – inspired by natural killer cell biology – advances gene-engineering science beyond current CAR T therapies, which are single chain and limited by "always-on" tonic signaling, T cell exhaustion, and the inability
More news about: Verismo Therapeutics
Mar 17, 2026, 15:00 ET Chega ao Brasil eplontersena para tratamento da amiloidose hereditária mediada por transtirretina com polineuropatia (ATTRv-PN)
sintomas neurológicos e melhora na qualidade de vida, quando comparado ao grupo controle¹. A ATTRv é uma condição rara causada por alterações no gene da transtirretina, resultando na produção de proteínas que se depositam em nervos periféricos e outros órgãos, podendo levar à perda progressiva de
More news about: AstraZeneca
Mar 17, 2026, 14:50 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Mar 17, 2026, 10:01 ET Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight
prevalence of patients who might benefit from treatment.Approval of Gene Therapy VYJUVEK: Gene therapies for epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA-approved topical gene therapy.Launch of Epidermolysis Bullosa Drugs: The dynamics
More news about: DelveInsight Business Research, LLP
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
LinkedIn.About Apertura Gene TherapyApertura Gene Therapy develops genetic medicines and next-generation AAV capsids that engage human-relevant receptors, aiming to enable more effective and selective gene delivery. The company's lead capsid, TfR1 CapX, leverages
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy and Viralgen Announce Strategic Collaboration to Manufacture TfR1 CapX, a Next-Generation Capsid for Gene Therapies Designed to Treat Central Nervous System Diseases
LinkedIn.About Apertura Gene TherapyApertura Gene Therapy develops genetic medicines and next-generation AAV capsids that engage human-relevant receptors, aiming to enable more effective and selective gene delivery. The company's lead capsid, TfR1 CapX, leverages
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy y Viralgen anuncian una colaboración estratégica para la fabricación de TfR1 CapX
LinkedIn.Acerca de Apertura Gene TherapyApertura Gene Therapy desarrolla medicamentos genéticos y cápsides AAV de última generación que interactúan con receptores relevantes para el ser
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy und Viralgen kündigen strategische Zusammenarbeit zur Herstellung von TfR1 CapX an, einem Kapsid der nächsten Generation für Gentherapien zur Behandlung von Erkrankungen des zentralen Nervensystems
LinkedIn.Informationen zu Apertura Gene TherapyApertura Gene Therapy entwickelt genetische Arzneimittel und AAV-Kapsiden der nächsten Generation, die an für den Menschen relevante Rezeptoren angreifen,
More news about: Viralgen
Mar 17, 2026, 09:00 ET Apertura Gene Therapy et Viralgen annoncent une collaboration stratégique pour la fabrication de TfR1 CapX, une capside de nouvelle génération pour les thérapies géniques destinées à traiter les maladies du système nerveux central.
LinkedIn.À propos d'Apertura Gene TherapyApertura Gene Therapy développe des médicaments génétiques et des capsides AAV de nouvelle génération qui engagent des récepteurs pertinents pour
More news about: Viralgen
Mar 17, 2026, 09:00 ET RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Mar 17, 2026, 09:00 ET Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson's Research
leaders, and provide preclinical and clinical resources to establish best practices for advancing LRRK2-targeted therapeutics. Mutations in the LRRK2 gene linked to Parkinson's disease were first discovered in 2004 and are now understood to be the most common cause of inherited Parkinson's disease. Built
More news about: Metabolon, Inc.